Evidence map›Paper›PMID 30868739›Full record

ArticleJournal of the International AIDS Society2019

Improvements in the HIV care continuum needed to meaningfully reduce HIV incidence among men who have sex with men in Baltimore, US: a modelling study for HPTN 078.

Kate M Mitchell, Brooke Hoots, Dobromir Dimitrov, Danielle German, Colin Flynn, Jason E Farley, Marcy Gelman, James P Hughes, Deborah Donnell, Adeola Adeyeye and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the International AIDS Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. How Can Progress Toward Ending the Human Immunodeficiency Virus Epidemic in the United States Be Monitored?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Kate M MitchellDepartment of Infectious Disease Epidemiology, Imperial College London, HPTN Modelling Centre, London, UK.ORCID 0000-0002-7050-4787
Brooke HootsDivision of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Dobromir DimitrovVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Danielle GermanDepartment of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Colin FlynnCenter for HIV Surveillance, Epidemiology and Evaluation, Maryland Department of Health, Baltimore, MD, USA.
Jason E FarleyDepartment of Community-Public Health, Johns Hopkins University School of Nursing, Baltimore, MD, USA.
Marcy GelmanThe Fenway Institute, Fenway Health, Boston, MA, USA.
James P HughesVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Deborah DonnellVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Adeola AdeyeyeDivision of AIDS, NIAID, National Institutes of Health, Washington, DC, USA.
Robert H RemienHIV Center for Clinical and Behavioral Studies, NY State Psychiatric Institute, New York, NY, USA.
Chris BeyrerDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Gabriela Paz-BaileyDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Marie-Claude BoilyDepartment of Infectious Disease Epidemiology, Imperial College London, HPTN Modelling Centre, London, UK.
Johns Hopkins University · USCenters for Disease Control and Prevention · USFred Hutch Cancer Center · USNIHR Imperial Biomedical Research Centre · GBFenway Health · USMaryland Department of Health · USNational Institutes of Health · USNew York Psychoanalytic Society and Institute · USUniversity of Washington · US

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Social networks, social resources, and HIV transmissionK01DA041259 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GERMAN, DANIELLE · 2016 to 2020
$829k
Medical Research Council MR/R015600/1NIAID NIH HHS P30 AI094189NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIDA NIH HHS K01 DA041259
6 · The paper itself

Abstract

introductionHIV prevalence is high among men who have sex with men (MSM) in Baltimore, Maryland, United States, and the levels of viral suppression among HIV-positive MSM are relatively low. The HIV Prevention Trials Network 078 trial seeks to increase the levels of viral suppression among US MSM by increasing the rates of diagnosis and linkage to care and treatment. We estimated the increases in viral suppression needed to reach different HIV incidence reduction targets, and the impact of meeting diagnosis and treatment targets.

methodsWe used a mathematical model of HIV transmission among MSM from Baltimore, US, parameterised with behavioural data and fitted to HIV prevalence and care continuum data for Baltimore wherever possible, to project increases in viral suppression needed to reduce the HIV incidence rate among Baltimore MSM by 10, 20, 30 or 50% after 2, 5 and 10 years. We also projected HIV incidence reductions achieved if US national targets - 90% of people living with HIV (PLHIV) know their HIV serostatus, 90% of those diagnosed are retained in HIV medical care and 80% of those diagnosed are virally suppressed - or UNAIDS 90-90-90 targets (90% of PLHIV know their status, 90% of those diagnosed receive antiretroviral therapy (ART), 90% of those receiving ART are virally suppressed) are each met by 2020.

resultsTo reduce the HIV incidence rate by 20% and 50% after five years (compared with the base-case at the same time point), the proportion of all HIV-positive MSM who are virally suppressed must increase above 2015 levels by a median 13 percentage points (95% uncertainty interval 9 to 16 percentage points) from median 49% to 60%, and 27 percentage points (22 to 35) from 49% to 75% respectively. Meeting all three US or 90-90-90 UNAIDS targets results in a 48% (31% to 63%) and 51% (38% to 65%) HIV incidence rate reduction in 2020 respectively.

conclusionsSubstantial improvements in levels of viral suppression will be needed to achieve significant incidence reductions among MSM in Baltimore, and to meet 2020 US and UNAIDS targets. Future modelling studies should additionally consider the impact of pre-exposure prophylaxis for MSM.

Indexed as

AdultAnti-HIV AgentsBaltimoreContinuity of Patient CareHIV InfectionsHomosexuality, MaleHumansIncidenceMaleMiddle AgedModels, TheoreticalPre-Exposure ProphylaxisPrevalenceUnited StatesAnti-HIV AgentsforecastingHIV infectionshomosexuality, maleincidencemodels, theoreticalUnited States

Identifiers

PMID30868739
PMCPMC6416473
OpenAlexW2921728829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.